Financial Performance - The company's operating revenue for 2023 is expected to be CNY 215.20 million, a decrease of 18.61% compared to the previous year[5]. - The net profit attributable to shareholders is expected to be CNY 85.47 million, down 24.15% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be CNY 84.36 million, a decrease of 23.00%[6]. - The basic earnings per share is expected to be CNY 1.42, a decline of 24.47% compared to the previous year[5]. Assets and Equity - Total assets at the end of the reporting period are expected to be CNY 307.47 million, an increase of 6.07% year-on-year[5]. - Shareholders' equity attributable to the company is expected to be CNY 285.11 million, up 10.51% from the beginning of the period[5]. - The expected net asset per share attributable to shareholders is CNY 4.75, reflecting a growth of 10.47%[5]. Impact Factors - The decline in operating performance is primarily due to the impact of the Russia-Ukraine conflict, which has affected customer purchasing volumes[5][6]. Cautionary Notes - The company warns that the financial data presented is preliminary and unaudited, and final figures may differ[7]. - The company emphasizes the need for investors to be aware of investment risks due to potential discrepancies in reported data[7].
海昇药业(870656) - 2023 Q4 - 年度业绩